Find research datasets worth reusing

The Effects of Disease Management Programs for Prevention of Recurrent Ischemic Stroke

ClinicalTrials.gov study NCT02121327. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.

Moyamoya Disease Biomarkers in Patients With Intracranial Atherosclerotic Stroke

ClinicalTrials.gov study NCT02074111. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Hypnosis and Attention in Patients With a Neurological Disease (Stroke, Traumatic Brain Injury and Multiple Sclerosis)

ClinicalTrials.gov study NCT07256704. IPD Sharing: UNDECIDED. Countries: 1. Publications: 12.

Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound

ClinicalTrials.gov study NCT00152113. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care

ClinicalTrials.gov study NCT05967728. IPD Sharing: NO. Countries: 1. Publications: 1.

Intensive Blood Pressure Control in Ischaemic Stroke Patients With Severe Cerebral Small Vessel Disease

ClinicalTrials.gov study NCT05690997. IPD Sharing: NO. Countries: 1. Publications: 25.

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

ClinicalTrials.gov study NCT04142125. IPD Sharing: NO. Countries: 1. Publications: 1.

The Role of Periodontal Diseases and Stimulation of Saliva Secretion in the Acute Phase of Ischemic Stroke

ClinicalTrials.gov study NCT05394090. IPD Sharing: NO. Countries: 1. Publications: 10.

Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa

ClinicalTrials.gov study NCT02675790. IPD Sharing: NO. Countries: 1. Publications: 3.

Stroke in Young Fabry Patients (sifap1): Frequency of Fabry Disease in Young Stroke Patients

ClinicalTrials.gov study NCT00414583. IPD Sharing: Not stated. Countries: 14. Publications: 20.

opencc-zeroDec 2018View details →

Data from: Relative effects of LDL-C on ischaemic stroke & coronary disease: a Mendelian randomization study

Objective: To examine the causal relevance of lifelong differences in LDL-C for ischaemic stroke (IS) relative to that for coronary heart disease (CHD) using a Mendelian randomization approach. Methods: We undertook a two-sample Mendelian randomization, based on summary data, to estimate the causal relevance of LDL-C for risk of IS and CHD. Information from 62 independent genetic variants with genome-wide significant effects on LDL-C levels was used to estimate the causal effects of LDL-C for IS and IS subtypes (based on 12,389 IS cases from METASTROKE) and for CHD (based on 60,801 cases from CARDIoGRAMplusC4D). We then assessed the effects of LDL-C on IS and CHD for heterogeneity. Results: A 1 mmol/L higher genetically-determined LDL-C was associated with a 50% higher risk of CHD (OR: 1.49, 95%CI: 1.32-1.68, p=1.1x10-8). By contrast, the causal effect of LDL-C was much weaker for IS (OR: 1.12, 95%CI: 0.96-1.30, p=0.14; p for heterogeneity=2.6x10-3) and, in particular, for cardioembolic stroke (OR: 1.06, 95%CI: 0.84-1.33, p=0.64; p for heterogeneity=8.6x10-3) when compared with that for CHD. Conclusions: In contrast with the consistent effects of LDL-C lowering therapies on IS and CHD, genetic variants that confer lifelong LDL-C differences show a weaker effect on IS than on CHD. The relevance of aetiologically distinct IS subtypes may contribute to the differences observed.

opencc-zeroAug 2021View details →

Risk of hemorrhagic and ischemic stroke in patients with Alzheimer disease: A synthesis of the literature

Objective To assess the risk of hemorrhagic and ischemic stroke in patients with Alzheimer disease (AD) compared to non-AD subjects with similar risk profiles. Methods A search was conducted on Embase and Medline for reports published up to September 26, 2018. Studies were included if they: 1) assessed incidence of stroke in patients diagnosed with AD; 2) included patients with no history of stroke; and 3) reported outcomes by stroke subtype. The main outcome was relative risk of ischemic or hemorrhagic stroke. Further, the rate of stroke occurrence per 1000 person-years was assessed. A random effects meta-analysis was undertaken. The risk of bias in included studies was assessed in terms of selection, comparability and outcome. Results 3,605 studies were screened in the title and abstract phase after removing duplicates, and 88 eligible studies were screened for full text. Eight studies met the inclusion criteria representing 121,719 subjects (AD=73,044; non-AD=48,675). Five studies were included in the relative risk analysis, among which four studies applied formal matching criteria of 44,544 AD and 44,660 non-AD subjects. The included studies were based on nation-wide registries from Finland, Sweden, Taiwan (2), UK (2), one clinic-based study from the Netherlands and one US population-based cohort. Among AD patients, the incidence rate of hemorrhagic stroke was 3.41/1000-person years (95% CI 2.70, 4.32) and 2.23 (95% CI 1.72, 2.88) among AD-cases and non-AD controls respectively. This is in contrast to 13.98 (95% CI 9.86, 19.81) and 12.12 (95% CI 7.55, 19.46) for ischemic stroke among AD-cases and non-AD controls respectively. Compared to non-AD subjects with similar risk profiles, AD patients had a relative risk of 1.42 (95% CI 1.23, 1.64) for hemorrhagic stroke and 1.15 (95% CI 0.89, 1.48) for ischemic stroke. Conclusion Compared to non-AD subjects with similar risk profiles, AD patients are likely at higher risk of hemorrhagic, but not ischemic stroke.

opencc-zeroSep 2021View details →

Cerebral small vessel disease MRI features do not improve the prediction of stroke outcome

Objective: To determine whether the total small vessel disease (SVD) score adds information to the prediction of stroke outcome compared to validated predictors, we tested different predictive models of outcome in stroke patients. Methods: White matter hyperintensity, lacunes, perivascular spaces, microbleeds, and atrophy were quantified in two prospective datasets of 428 and 197 first-ever stroke patients, using MRI collected 24-to-72 hours after stroke onset. Functional, cognitive, and psychological status were assessed at the 3–6 month follow-up. The predictive accuracy (in terms of calibration and discrimination) of age, baseline NIHSS, and infarct volume was quantified (model-1) on dataset-1, the total SVD score was added (model-2), and the improvement in predictive accuracy was evaluated. These two models were also developed in dataset-2 for replication. Finally, in model-3, the MRI features of cerebral SVD were included rather than the total SVD score. Results: Model-1 showed excellent performance for discriminating poor vs. good functional outcomes (AUC=0.915), and fair performance for identifying cognitively impaired and depressed patients (AUCs, 0.750 and 0.688 respectively). A higher SVD score was associated with a poorer outcome (odds ratio=1.30 [1.07, 1.58], p=0.0090 at best for functional outcome). However, adding the total SVD score (model-2) or individual MRI features (model-3) did not improve the prediction over model-1. Results for dataset-2 were similar. Conclusions: Cerebral SVD was independently associated with functional, cognitive, and psychological outcomes, but had no clinically relevant added value to predict the individual outcomes of patients when compared to the usual predictors, such as age and baseline NIHSS.

ClinicalTrials.gov28/100

Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients

ClinicalTrials.gov study NCT01419275. IPD Sharing: Not stated. Countries: 1. Publications: 0.

ClinicalTrials.gov28/100

Multifactorial Risk Stratification in Stroke Patients With Cardiac Disease

ClinicalTrials.gov study NCT04352790. IPD Sharing: UNDECIDED. Countries: 0. Publications: 2.

controlledIPD-YESFeb 2026View details →

ClinicalTrials.gov28/100

Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

ClinicalTrials.gov study NCT06638944. IPD Sharing: YES. Countries: 1. Publications: 0.

publicSep 2021View details →

Cerebral small vessel disease MRI features do not improve the prediction of stroke outcome

Open the record for dataset details and reuse information.

publicMar 2019View details →

Data from: Relative effects of LDL-C on ischaemic stroke & coronary disease: a Mendelian randomization study

Open the record for dataset details and reuse information.

publicAug 2019View details →

Data from: Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke

Open the record for dataset details and reuse information.